BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aben KK, Heskamp S, Janssen-Heijnen ML, Koldewijn EL, van Herpen CM, Kiemeney LA, Oosterwijk E, van Spronsen DJ. Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur J Cancer. 2011;47:2023-2032. [PMID: 21459570 DOI: 10.1016/j.ejca.2011.03.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 van den Brom R, van Es S, Leliveld A, Gietema J, Hospers G, de Jong I, de Vries E, Oosting S. Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma. Cancer Treatment Reviews 2016;46:63-72. [DOI: 10.1016/j.ctrv.2016.04.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
2 Conti SL, Thomas IC, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, Brooks JD, Srinivas S, Leppert JT. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer 2014;134:2245-52. [PMID: 24135850 DOI: 10.1002/ijc.28553] [Cited by in Crossref: 74] [Cited by in F6Publishing: 71] [Article Influence: 9.3] [Reference Citation Analysis]
3 Shen J, Chen Z, Zhuang Q, Fan M, Ding T, Lu H, He X. Prognostic Value of Serum Lactate Dehydrogenase in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0166482. [PMID: 27861542 DOI: 10.1371/journal.pone.0166482] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
4 Kuznetsov HS, Marsh T, Markens BA, Castaño Z, Greene-Colozzi A, Hay SA, Brown VE, Richardson AL, Signoretti S, Battinelli EM, McAllister SS. Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov 2012;2:1150-65. [PMID: 22896036 DOI: 10.1158/2159-8290.CD-12-0216] [Cited by in Crossref: 83] [Cited by in F6Publishing: 55] [Article Influence: 8.3] [Reference Citation Analysis]
5 Verzoni E, Ratta R, Grassi P, Salvioni R, Stagni S, Montone R, Fucà G, Cappelletti V, Reduzzi C, De Giorgi U, Procopio G. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery. Tumori 2018;104:401-5. [DOI: 10.5301/tj.5000699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
6 Chatzizacharias NA, Rosich-Medina A, Dajani K, Harper S, Huguet E, Liau SS, Praseedom RK, Jah A. Surgical management of hepato-pancreatic metastasis from renal cell carcinoma. World J Gastrointest Oncol 2017; 9(2): 70-77 [PMID: 28255428 DOI: 10.4251/wjgo.v9.i2.70] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
7 Tatsugami K, Shinohara N, Kondo T, Yamasaki T, Eto M, Tsushima T, Terachi T, Naito S; the Japanese Society of Renal Cancer. Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era: Cytoreductive nephrectomy for Japanese patients. Int J Urol 2015;22:736-40. [DOI: 10.1111/iju.12803] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
8 Xue J, Chen W, Xu W, Xu Z, Li X, Qi F, Wang Z. Patterns of distant metastases in patients with clear cell renal cell carcinoma--A population-based analysis. Cancer Med 2021;10:173-87. [PMID: 33247630 DOI: 10.1002/cam4.3596] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 de Bruijn RE, Nijkamp J, Noe A, Horenblas S, Haanen JB, Prevoo W, Bex A. Baseline tumor volume in assessing prognosis of patients with intermediate-risk synchronous metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2016;34:258.e7-258.e13. [DOI: 10.1016/j.urolonc.2015.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
10 Khochikar MV. Cytoreductive Surgery in the Management of Renal Tumours: Rationale, Current Evidence and Future Perspectives. Indian J Surg Oncol 2017;8:33-8. [PMID: 28127180 DOI: 10.1007/s13193-016-0592-3] [Reference Citation Analysis]
11 Hatzaras I, Gleisner AL, Pulitano C, Sandroussi C, Hirose K, Hyder O, Wolfgang CL, Aldrighetti L, Crawford M, Choti MA, Pawlik TM. A multi-institution analysis of outcomes of liver-directed surgery for metastatic renal cell cancer. HPB (Oxford). 2012;14:532-538. [PMID: 22762401 DOI: 10.1111/j.1477-2574.2012.00495.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
12 Andrushchuk U, Ostrovsky Y, Krasny S, Polyakov S, Zharkov V, Rolevich A, Kurganovich S, Krutau V, Amelchanka SG. Simultaneous or staged surgery in patients with kidney tumors and concomitant cardiac disease. Cent European J Urol 2017;70:356-61. [PMID: 29410885 DOI: 10.5173/ceju.2017.1337] [Reference Citation Analysis]
13 Bex A, Haanen J. Do targeted agents offer clinical benefit as presurgical therapy? World J Urol 2014;32:3-8. [DOI: 10.1007/s00345-013-1041-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
14 Wu M, Liu J, Seery S, Meng X, Yue J. Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature. Front Immunol 2021;12:646085. [PMID: 34211459 DOI: 10.3389/fimmu.2021.646085] [Reference Citation Analysis]
15 Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, Choueiri TK. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int 2014;113:E67-74. [PMID: 24053727 DOI: 10.1111/bju.12442] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
16 Bex A, Powles T. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Expert Rev Anticancer Ther 2012;12:787-97. [PMID: 22716495 DOI: 10.1586/era.12.54] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
17 Manley BJ, Kim EH, Vetter JM, Potretzke AM, Strope SA. Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA. Int Braz J Urol 2017;43:432-9. [PMID: 28128914 DOI: 10.1590/S1677-5538.IBJU.2015.0118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
18 Xiao WJ, Zhu Y, Dai B, Zhang HL, Ye DW. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis. Int Braz J Urol 2015;41:288-95. [PMID: 26005970 DOI: 10.1590/S1677-5538.IBJU.2015.02.15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
19 van de Schans SA, Aben KK, Mulders PF, Haanen JB, van Herpen C, Verhoeven RH, Karim-Kos HE, Oosterwijk E, Kiemeney LA. Modest improvement in 20 years of kidney cancer care in the Netherlands. Eur J Cancer 2012;48:1822-30. [PMID: 22365640 DOI: 10.1016/j.ejca.2012.01.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
20 Brouwer OR, van der Poel HG, Bevers RF, van Gennep EJ, Horenblas S. Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies? Clin Transl Imaging 2016;4:395-410. [PMID: 27738628 DOI: 10.1007/s40336-016-0189-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Moschini M, Morlacco A, Kwon E, Rangel LJ, Karnes RJ. Treatment of M1a/M1b prostate cancer with or without radical prostatectomy at diagnosis. Prostate Cancer Prostatic Dis 2017;20:117-21. [DOI: 10.1038/pcan.2016.63] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
22 Zhang N, Zhang H, Zhu D, JiRiGaLa, Yu D, Wang C, WuYunBiLiGe, Amin, ZhiHong, Yu H, Chen X, Wang M. Prognostic role of pretreatment lactate dehydrogenase in patients with metastatic renal cell carcinoma: A systematic review and meta-analysis. Int J Surg 2020;79:66-73. [PMID: 32417461 DOI: 10.1016/j.ijsu.2020.05.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Minnillo BJ, Tabayoyong W, Francis JJ, Maurice MJ, Zhu H, Kim S, Abouassaly R. Cytoreductive nephrectomy in the modern era: Predictors of use, morbidity, and survival. Can Urol Assoc J 2017;11:E184-91. [PMID: 28503232 DOI: 10.5489/cuaj.4137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Casuscelli J, Gratzke C, Stief CG, Staehler M. [Partial nephrectomy. Rationale and limitations of an organ-preserving approach]. Urologe A 2012;51:1194-201. [PMID: 22669250 DOI: 10.1007/s00120-012-2873-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
25 Huber J, Groeben C, Wirth MP. [Removal of the primary tumor in hematogenous metastatic tumor disease: reasons against]. Urologe A 2014;53:840-6. [PMID: 24841423 DOI: 10.1007/s00120-014-3548-7] [Reference Citation Analysis]